Moderna-Merck Melanoma Vaccine Trial Data Leaked Ahead of Release
Some Phase 3 clinical trial data on the Moderna and Merck melanoma vaccine leaked before the official announcement. The two companies released the clinical data early after the leak. Both companies' shares fell around the leak, and Moderna's share price appeared to stabilise on 27 October.
Key facts
- Affected organisation
- Moderna
- Incident type
- Data breach
- Occurred / detected
- Not confirmed
- Scale of damage
- Some Phase 3 melanoma vaccine trial data leaked early, and share prices fell
- Cause / method
- Not confirmed
- Location
- United States
If your data was exposed
Exposed dataHealth & medical data
- Don’t tap links in texts, calls or emails that mention this incident and offer compensation, refunds or breach checks. Check directly on the organisation’s official website or app.
Timeline
- Moderna and Merck shares fell after the melanoma vaccine data leak.
- Moderna and Merck released the Phase 3 vaccine trial data early after the leak.
- Moderna's share price, which had plunged after the data leak, appeared to stabilise.
29 related reports
- Watch Moderna, Merck Fall After Melanoma Data Leak
- Moderna Stock Sinks Following Vaccine Data Leak
- Moderna, Merck Shares Fall After Possible Melanoma Data Leak
- Moderna Stock Plunges 25% After Possible Cancer Vaccine Data Leak
- Moderna shares plunge on leaked cancer vaccine data (MRNA:NASDAQ)
- Moderna shares plunge after cancer vaccine data leaks — despite positive results
- Moderna Stock Plunges as Apparent Leak Reveals Phase 3 Melanoma Vaccine Data
- Moderna shares plunge on partial leak of cancer vaccine data
- Merck, Moderna Unveil Cancer Vaccine Data — After A Leak Stole Their Thunder
- Moderna’s cancer vaccine hits its targets, but a data leak rattled investors and the stock tumbled
- ESMO: After leak, Merck and Moderna post phase 3 cancer vaccine data early
- Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data
- Moderna, Merck Shares Fall as Leaked Cancer Data Disappoints
- ESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak
- Moderna plunges after cancer vaccine data leak, even as results top the Street's bar
- Moderna shares sink after leaked cancer data missed expectations
- Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports
- Moderna, Merck Cancer Vaccine Data Unveiled Early After Leak, Causing Stock Slump
- ESMO26: Moderna, MSD reveal cancer jab data early after leak
- Moderna shares plunge on cancer vaccine data leak
- Moderna Stock Cools After Cancer Vaccine Data Leak
- Moderna shares continue to fall after early cancer vaccine data leak
- Moderna Stock Plummets After Cancer-Vaccine Data Leak
- William Blair analyst on Moderna’s stock plunge following cancer vaccine data leaks
- Moderna’s Cancer-Vaccine Leak Spurs Panic Selling. Wall Street Wanted a Cure.
- ‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
- Moderna (MRNA) Stock May Be Fully Priced As Melanoma Vaccine Data Leaks
- ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak
- Moderna shares steady after ESMO data leak crash
The summary and key facts are written by AI from related reports and may contain errors. Check the original articles and the organisation’s official statements for accurate details.